pH/redox sensitive nanoparticles with platinum(iv) prodrugs and doxorubicin enhance chemotherapy in ovarian cancer
نویسندگان
چکیده
منابع مشابه
Prodrugs in cancer chemotherapy.
Many drugs used in cancer chemotherapy are general cytotoxic agents and do not have any specific activity towards tumour cells. The aim of the medicinal chemist working in this field is therefore to design structures which will exploit the minor differences between normal and neoplastic cells, as and when they are described by the biochemist. The pharmacologist is also involved in describing th...
متن کاملNanocarriers enhance Doxorubicin uptake in drug-resistant ovarian cancer cells.
Resistance to anthracyclines and other chemotherapeutics due to P-glycoprotein (pgp)-mediated export is a frequent problem in cancer treatment. Here, we report that iron oxide-titanium dioxide core-shell nanocomposites can serve as efficient carriers for doxorubicin to overcome this common mechanism of drug resistance in cancer cells. Doxorubicin nanocarriers (DNC) increased effective drug upta...
متن کاملPolymer-Based Prodrugs for Cancer Chemotherapy
Chemotherapy has achieved great success in cancer treatment during recent past decades, but it is still challenged by poor solubility, low tumor selectivity, and associated toxicity of most anticancer drugs. The prodrug strategy is one of the most commonly used chemical/biochemical strategies towards improving the therapeutic index of anticancer drugs. A prodrug is defined as a chemically modif...
متن کاملProtease-activated "prodrugs" for cancer chemotherapy.
Many types of malignant cells and human tumors display increased concentrations of the protease plasminogen activator that converts plasminogen to the highly active protease, plasmin. Because plasmin rapidly cleaves various low molecular weight compounds coupled to appropriate peptide specifiers, we hypothesized that coupling of such peptide specifiers to anticancer drugs might create "prodrugs...
متن کاملDoxorubicin synergizes with 34.5ENVE to enhance antitumor efficacy against metastatic ovarian cancer.
PURPOSE Novel therapeutic regimens are needed to improve dismal outcomes associated with late-stage ovarian cancer. Oncolytic viruses are currently being tested in patients with ovarian cancer. Here, we tested the therapeutic efficacy of combining doxorubicin with 34.5ENVE, an oncolytic herpes simplex virus transcriptionally driven by a modified stem cell-specific nestin promoter, and encoding ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: RSC Advances
سال: 2019
ISSN: 2046-2069
DOI: 10.1039/c9ra04034j